Glow-in-the-Dark drug could help surgeons spot hidden ovarian cancer

NCT ID NCT05804370

First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 25 times

Summary

This study tests a drug called Gleolan that makes ovarian cancer cells glow during surgery, helping surgeons see and remove tumors they might otherwise miss. About 170 adults with suspected or confirmed ovarian cancer will take part. The goal is to see if Gleolan improves tumor removal and is safe to use.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Luminis Health Anne Arundel Medical Center

    TERMINATED

    Annapolis, Maryland, 21401, United States

  • Mayo Clinic Arizona

    RECRUITING

    Phoenix, Arizona, 85054, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Mayo Clinic Methodist Campus

    RECRUITING

    Rochester, Minnesota, 55905, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Mount Sinai

    RECRUITING

    New York, New York, 10128, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • University of Maryland

    RECRUITING

    Baltimore, Maryland, 21201, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • WellSpan Health

    RECRUITING

    York, Pennsylvania, 17403, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.